DERM News & Events

After two consecutive losing session, major indices roared back on Thursday, with strong results out of TSMC bolstering the capex investment theme in semiconductors - semi equipment names such as Applied Materialsand KLA Corpwere some of the strongest performers on the S&P 500.   Sentiment in Financials also rebounded in the wake of broad post-earnings selling in shares of JPMorganand Citias Goldman Sachsand Blackrockrallies on strong Q4 numbers picked up the slack.  Major Regionals like PNC Financialand Regionsare on tap to report results on Friday morning.In the opening hour of the evening session, S&P e-minis and Dow Industrials are sustaining the upward momentum with modest gains, up 0.1%, and Nasdaq 100 is up 0.2%.  In precious metals, Gold and Silver are coiling just below the all-time highs seen earlier this week.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER -Sylvamoup 2.0% after 2026 outlookDOWN AFTER EARNINGS -J.B. Hunt Transportdown 4.3%WaFddown 0.5%ALSO LOWER -QXOdown 4.2% after Q4 pre-announcement, $750M stock offeringDogwood Therapeuticsdown 2.1% after equity offeringJourney Medicaldown 2.0% after equity offeringWoodwarddown 1.5% after announcing winddown of China gas truck business

Journey Medical files $150M mixed securities shelf

Journey Medical announced that results from the Phase 1 clinical trial assessing the impact of low-dose oral minocycline, DFD-29, on skin, gastrointestinal and vaginal microflora in healthy adults were published in the Journal of Drugs in Dermatology, a leading peer-reviewed publication in clinical dermatology. The clinical trial also assessed the safety and tolerability of the treatment. The results indicate that DFD-29 administration for 16 weeks had no detectable effects on skin, GI tract or vaginal microflora and it was well tolerated in healthy adults, supporting its use as a therapeutic option for patients with moderate-to-severe rosacea. "We are very pleased to see these important data published in the Journal of Drugs in Dermatology," said Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical. "This peer-reviewed validation reinforces the differentiated profile of Emrosi as an effective, low-dose oral treatment for rosacea that does not meaningfully disrupt the normal microbiota or contribute to antibiotic resistance. These results, along with the robust safety and efficacy data seen throughout all of our clinical trials, further support Emrosi's potential for long-term use and underscore our commitment to bringing safe, innovative dermatology treatments to patients."